Trial Profile
A Phase I Study to Investigate the Safety, Pharmacokinetic Profile and the Efficacy of EDO-S101, a First-in-Class Alkylating HDACi Fusion Molecule in Patients With Newly Di-Agnosed MGMT-Promoter Unmethylated Glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs Tinostamustine (Primary)
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions
- 04 Apr 2023 Planned End Date changed from 31 Oct 2022 to 30 Dec 2024.
- 04 Apr 2023 Planned primary completion date changed from 31 Oct 2022 to 30 Dec 2024.
- 16 May 2022 Planned number of patients changed from 128 to 92.